항VEGF 시장 : 세계 산업 분석, 시장 규모, 점유율, 성장, 동향, 예측(2025-2032년)

Persistence Market Research has recently released a comprehensive report on the worldwide market for anti-VEGF (vascular endothelial growth factor) therapeutics. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure.

Key Insights:

• Anti-VEGF Market Size (2025E): USD 25.2 Billion
• Projected Market Value (2032F): USD 33.1 Billion
• Global Market Growth Rate (CAGR 2025 to 2032): 4.0%

Anti-VEGF Market - Report Scope:

Anti-VEGF therapies are widely used in the treatment of various retinal disorders, cancers, and other diseases associated with abnormal blood vessel growth. These therapies inhibit the action of VEGF, a protein that promotes angiogenesis, thereby helping control disease progression. The anti-VEGF market spans ophthalmology, oncology, and nephrology segments, with major applications in age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and colorectal and lung cancers. Market growth is fueled by the rising prevalence of chronic diseases, expanding elderly population, and increasing use of biologics in targeted therapy.

Market Growth Drivers:

The global anti-VEGF market is propelled by several key factors, including the growing incidence of retinal disorders such as AMD and DME, especially among the aging population. Increased healthcare awareness and improved diagnostic technologies have enhanced early detection rates, leading to greater adoption of anti-VEGF therapies. In oncology, the rising burden of cancers and demand for precision medicine contribute significantly to market expansion. Moreover, the launch of new biosimilars and next-generation anti-VEGF agents offering extended durability and fewer injections are further accelerating market penetration.

Market Restraints:

Despite strong growth prospects, the anti-VEGF market faces several challenges. High treatment costs and frequent dosing regimens can hinder patient adherence and limit market access, particularly in developing regions. Patent expirations of blockbuster biologics such as Avastin and Lucentis introduce pricing pressures and competitive threats from biosimilars. Additionally, side effects associated with long-term anti-VEGF use, including increased intraocular pressure and risk of geographic atrophy, present safety concerns that may restrain widespread use in some patient populations.

Market Opportunities:

The anti-VEGF market offers substantial growth opportunities driven by ongoing research in combination therapies and novel delivery systems such as sustained-release implants and gene therapies. Expanding clinical indications for anti-VEGF agents, including treatment for myopic choroidal neovascularization and nephropathy, broaden the potential market. The increasing regulatory approvals of biosimilars across regions and rising healthcare investments in emerging economies create a favorable environment for manufacturers to enhance accessibility and affordability. Strategic collaborations with academic institutions and biotechnology firms are crucial for fostering innovation and pipeline development.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the anti-VEGF market globally?
• Which therapeutic areas and indications are most influenced by anti-VEGF adoption?
• How are biosimilars and new formulations impacting the competitive landscape of the anti-VEGF market?
• Who are the leading players in the anti-VEGF market and what strategies are they pursuing to retain market share?
• What are the future prospects and emerging trends within the global anti-VEGF therapeutics space?

Competitive Intelligence and Business Strategy:

These firms are investing in clinical trials for newer indications, exploring combination regimens, and advancing drug delivery innovations to enhance efficacy and patient convenience. Collaborations with contract manufacturing organizations, healthcare institutions, and regulatory authorities enable streamlined development and market access strategies. Additionally, competitive pricing, co-pay assistance programs, and patient support initiatives are being employed to improve adoption and treatment outcomes across various demographic and economic segments.

Key Companies Profiled:

• Pfizer Inc.
• Bayer AG
• Novartis AG
• Sanofi SA
• Exelixis Inc.
• Eisai Co. Ltd.
• Amgen Inc.
• F. Hoffmann-La Roche Ltd.
• Eli Lilly and Company
• Amneal Pharmaceuticals Inc.
• Jiangsu Hengrui Pharmaceuticals Co. Ltd.
• Takeda Pharmaceutical Co. Ltd.
• Sino Biopharma
• HUTCHMED

Anti-VEGF Market Research Segmentation:

By Drug:

• Small Molecules

* Pazopanib

* Sunitinib

* Sorafenib

* Regorafenib

* Cabozantinib

* Lenvatinib

* Ponatinib

* Cabozantinib

* Axitinib

* Tivozanib

* Vandetanib

* Anlotinib

* Apatinib

* Fruquintinib

* Surufatinib

• Biologics

* Bevacizumab

* Aflibercept

* Ramucirumab

By Type:

• VEGF-A Inhibitors
• VEGF-B Inhibitors
• VEGF-C Inhibitors
• Placenta Growth Factor Inhibitors

By Disease Indication:

• Oncology

* Non-Small Cell Lung Cancer

* Renal Cell Carcinoma

* Colorectal Cancer

* Hepatocellular Carcinoma

* Cervical Cancer

* Others

• Hematology Disorders
• Ophthalmology Disorders

* Wet Age-related Macular Degeneration (AMD)

* Diabetic Retinopathy

* Others

By Distribution Channel:

• Hospitals
• Specialty Clinics
• Mail Order Pharmacies

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East and Africa

Table of Contents

1. Executive Summary

• 1.1. Global Anti-VEGF Market Snapshot 2025 and 2032
• 1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
• 1.3. Key Market Trends
• 1.4. Industry Developments and Key Market Events
• 1.5. Demand Side and Supply Side Analysis
• 1.6. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definitions
• 2.2. Value Chain Analysis
• 2.3. Macro-Economic Factors
  • 2.3.1. Global GDP Outlook
  • 2.3.2. Global GDP Outlook
  • 2.3.3. Global economic Growth Forecast
  • 2.3.4. Global Urbanization Growth
  • 2.3.5. Other Macro-economic Factors
• 2.4. Forecast Factors - Relevance and Impact
• 2.5. COVID-19 Impact Assessment
• 2.6. PESTLE Analysis
• 2.7. Porter's Five Forces Analysis
• 2.8. Geopolitical Tensions: Market Impact
• 2.9. Regulatory and Technology Landscape

3. Market Dynamics

• 3.1. Drivers
• 3.2. Restraints
• 3.3. Opportunities
• 3.4. Trends

4. Price Trend Analysis, 2019-2032

• 4.1. Region-wise Price Analysis
• 4.2. Price by Segments
• 4.3. Price Impact Factors

5. Global Anti-VEGF Market Outlook: Historical (2019-2024) and Forecast (2025-2032)

• 5.1. Key Highlights
• 5.2. Global Anti-VEGF Market Outlook: Drug
  • 5.2.1. Introduction/Key Findings
  • 5.2.2. Historical Market Size (US$ Bn) Analysis by Drug, 2019-2024
  • 5.2.3. Current Market Size (US$ Bn) Forecast, by Drug, 2025-2032
    • 5.2.3.1. Small Molecules
      • 5.2.3.1.1. Pazopanib
      • 5.2.3.1.2. Sunitinib
      • 5.2.3.1.3. Sorafenib
      • 5.2.3.1.4. Regorafenib
      • 5.2.3.1.5. Cabozantinib
      • 5.2.3.1.6. Lenvatinib
    • 5.2.3.2. Biologics
      • 5.2.3.2.1. Bevacizumab
      • 5.2.3.2.2. Aflibercept
      • 5.2.3.2.3. Ramucirumab
  • 5.2.4. Market Attractiveness Analysis: Drug
• 5.3. Global Anti-VEGF Market Outlook: Type
  • 5.3.1. Introduction/Key Findings
  • 5.3.2. Historical Market Size (US$ Bn) Analysis by Type, 2019-2024
  • 5.3.3. Current Market Size (US$ Bn) Forecast, by Type, 2025-2032
    • 5.3.3.1. VEGF-A Inhibitors
    • 5.3.3.2. VEGF-B Inhibitors
    • 5.3.3.3. VEGF-C Inhibitors
    • 5.3.3.4. Placenta Growth Factor Inhibitors
  • 5.3.4. Market Attractiveness Analysis: Type
• 5.4. Global Anti-VEGF Market Outlook: Disease Indication
  • 5.4.1. Introduction/Key Findings
  • 5.4.2. Historical Market Size (US$ Bn) Analysis by Disease Indication, 2019-2024
  • 5.4.3. Current Market Size (US$ Bn) Forecast, by Disease Indication, 2025-2032
    • 5.4.3.1. Oncology
    • 5.4.3.2. Hematology Disorders
    • 5.4.3.3. Ophthalmology Disorders
  • 5.4.4. Market Attractiveness Analysis: Disease Indication
• 5.5. Global Anti-VEGF Market Outlook: Distribution Channel
  • 5.5.1. Introduction/Key Findings
  • 5.5.2. Historical Market Size (US$ Bn) Analysis by Distribution Channel, 2019-2024
  • 5.5.3. Current Market Size (US$ Bn) Forecast, by Distribution Channel, 2025-2032
    • 5.5.3.1. Hospitals
    • 5.5.3.2. Specialty Clinics
    • 5.5.3.3. Mail Order Pharmacies
  • 5.5.4. Market Attractiveness Analysis: Distribution Channel

6. Global Anti-VEGF Market Outlook: Region

• 6.1. Key Highlights
• 6.2. Historical Market Size (US$ Bn) Analysis by Region, 2019-2024
• 6.3. Current Market Size (US$ Bn) Forecast, by Region, 2025-2032
  • 6.3.1. North America
  • 6.3.2. Europe
  • 6.3.3. East Asia
  • 6.3.4. South Asia & Oceania
  • 6.3.5. Latin America
  • 6.3.6. Middle East & Africa
• 6.4. Market Attractiveness Analysis: Region

7. North America Anti-VEGF Market Outlook: Historical (2019-2024) and Forecast (2025-2032)

• 7.1. Key Highlights
• 7.2. Pricing Analysis
• 7.3. North America Market Size (US$ Bn) Forecast, by Country, 2025-2032
  • 7.3.1. U.S.
  • 7.3.2. Canada
• 7.4. North America Market Size (US$ Bn) Forecast, by Drug, 2025-2032
  • 7.4.1. Small Molecules
    • 7.4.1.1. Pazopanib
    • 7.4.1.2. Sunitinib
    • 7.4.1.3. Sorafenib
    • 7.4.1.4. Regorafenib
    • 7.4.1.5. Cabozantinib
    • 7.4.1.6. Lenvatinib
  • 7.4.2. Biologics
    • 7.4.2.1. Bevacizumab
    • 7.4.2.2. Aflibercept
    • 7.4.2.3. Ramucirumab
• 7.5. North America Market Size (US$ Bn) Forecast, by Type, 2025-2032
  • 7.5.1. VEGF-A Inhibitors
  • 7.5.2. VEGF-B Inhibitors
  • 7.5.3. VEGF-C Inhibitors
  • 7.5.4. Placenta Growth Factor Inhibitors
• 7.6. North America Market Size (US$ Bn) Forecast, by Disease Indication, 2025-2032
  • 7.6.1. Oncology
  • 7.6.2. Hematology Disorders
  • 7.6.3. Ophthalmology Disorders
• 7.7. North America Market Size (US$ Bn) Forecast, by Distribution Channel, 2025-2032
  • 7.7.1. Hospitals
  • 7.7.2. Specialty Clinics
  • 7.7.3. Mail Order Pharmacies

8. Europe Anti-VEGF Market Outlook: Historical (2019-2024) and Forecast (2025-2032)

• 8.1. Key Highlights
• 8.2. Pricing Analysis
• 8.3. Europe Market Size (US$ Bn) Forecast, by Country, 2025-2032
  • 8.3.1. Germany
  • 8.3.2. Italy
  • 8.3.3. France
  • 8.3.4. U.K.
  • 8.3.5. Spain
  • 8.3.6. Russia
  • 8.3.7. Rest of Europe
• 8.4. Europe Market Size (US$ Bn) Forecast, by Drug, 2025-2032
  • 8.4.1. Small Molecules
    • 8.4.1.1. Pazopanib
    • 8.4.1.2. Sunitinib
    • 8.4.1.3. Sorafenib
    • 8.4.1.4. Regorafenib
    • 8.4.1.5. Cabozantinib
    • 8.4.1.6. Lenvatinib
  • 8.4.2. Biologics
    • 8.4.2.1. Bevacizumab
    • 8.4.2.2. Aflibercept
    • 8.4.2.3. Ramucirumab
• 8.5. Europe Market Size (US$ Bn) Forecast, by Type, 2025-2032
  • 8.5.1. VEGF-A Inhibitors
  • 8.5.2. VEGF-B Inhibitors
  • 8.5.3. VEGF-C Inhibitors
  • 8.5.4. Placenta Growth Factor Inhibitors
• 8.6. Europe Market Size (US$ Bn) Forecast, by Disease Indication, 2025-2032
  • 8.6.1. Oncology
  • 8.6.2. Hematology Disorders
  • 8.6.3. Ophthalmology Disorders
• 8.7. Europe Market Size (US$ Bn) Forecast, by Distribution Channel, 2025-2032
  • 8.7.1. Hospitals
  • 8.7.2. Specialty Clinics
  • 8.7.3. Mail Order Pharmacies

9. East Asia Anti-VEGF Market Outlook: Historical (2019-2024) and Forecast (2025-2032)

• 9.1. Key Highlights
• 9.2. Pricing Analysis
• 9.3. East Asia Market Size (US$ Bn) Forecast, by Country, 2025-2032
  • 9.3.1. China
  • 9.3.2. Japan
  • 9.3.3. South Korea
• 9.4. East Asia Market Size (US$ Bn) Forecast, by Drug, 2025-2032
  • 9.4.1. Small Molecules
    • 9.4.1.1. Pazopanib
    • 9.4.1.2. Sunitinib
    • 9.4.1.3. Sorafenib
    • 9.4.1.4. Regorafenib
    • 9.4.1.5. Cabozantinib
    • 9.4.1.6. Lenvatinib
  • 9.4.2. Biologics
    • 9.4.2.1. Bevacizumab
    • 9.4.2.2. Aflibercept
    • 9.4.2.3. Ramucirumab
• 9.5. East Asia Market Size (US$ Bn) Forecast, by Type, 2025-2032
  • 9.5.1. VEGF-A Inhibitors
  • 9.5.2. VEGF-B Inhibitors
  • 9.5.3. VEGF-C Inhibitors
  • 9.5.4. Placenta Growth Factor Inhibitors
• 9.6. East Asia Market Size (US$ Bn) Forecast, by Disease Indication, 2025-2032
  • 9.6.1. Oncology
  • 9.6.2. Hematology Disorders
  • 9.6.3. Ophthalmology Disorders
• 9.7. East Asia Market Size (US$ Bn) Forecast, by Distribution Channel, 2025-2032
  • 9.7.1. Hospitals
  • 9.7.2. Specialty Clinics
  • 9.7.3. Mail Order Pharmacies

10. South Asia & Oceania Anti-VEGF Market Outlook: Historical (2019-2024) and Forecast (2025-2032)

• 10.1. Key Highlights
• 10.2. Pricing Analysis
• 10.3. South Asia & Oceania Market Size (US$ Bn) Forecast, by Country, 2025-2032
  • 10.3.1. India
  • 10.3.2. Southeast Asia
  • 10.3.3. ANZ
  • 10.3.4. Rest of SAO
• 10.4. South Asia & Oceania Market Size (US$ Bn) Forecast, by Drug, 2025-2032
  • 10.4.1. Small Molecules
    • 10.4.1.1. Pazopanib
    • 10.4.1.2. Sunitinib
    • 10.4.1.3. Sorafenib
    • 10.4.1.4. Regorafenib
    • 10.4.1.5. Cabozantinib
    • 10.4.1.6. Lenvatinib
  • 10.4.2. Biologics
    • 10.4.2.1. Bevacizumab
    • 10.4.2.2. Aflibercept
    • 10.4.2.3. Ramucirumab
• 10.5. South Asia & Oceania Market Size (US$ Bn) Forecast, by Type, 2025-2032
  • 10.5.1. VEGF-A Inhibitors
  • 10.5.2. VEGF-B Inhibitors
  • 10.5.3. VEGF-C Inhibitors
  • 10.5.4. Placenta Growth Factor Inhibitors
• 10.6. South Asia & Oceania Market Size (US$ Bn) Forecast, by Disease Indication, 2025-2032
  • 10.6.1. Oncology
  • 10.6.2. Hematology Disorders
  • 10.6.3. Ophthalmology Disorders
• 10.7. South Asia & Oceania Market Size (US$ Bn) Forecast, by Distribution Channel, 2025-2032
  • 10.7.1. Hospitals
  • 10.7.2. Specialty Clinics
  • 10.7.3. Mail Order Pharmacies

11. Latin America Anti-VEGF Market Outlook: Historical (2019-2024) and Forecast (2025-2032)

• 11.1. Key Highlights
• 11.2. Pricing Analysis
• 11.3. Latin America Market Size (US$ Bn) Forecast, by Country, 2025-2032
  • 11.3.1. Brazil
  • 11.3.2. Mexico
  • 11.3.3. Rest of LATAM
• 11.4. Latin America Market Size (US$ Bn) Forecast, by Drug, 2025-2032
  • 11.4.1. Small Molecules
    • 11.4.1.1. Pazopanib
    • 11.4.1.2. Sunitinib
    • 11.4.1.3. Sorafenib
    • 11.4.1.4. Regorafenib
    • 11.4.1.5. Cabozantinib
    • 11.4.1.6. Lenvatinib
  • 11.4.2. Biologics
    • 11.4.2.1. Bevacizumab
    • 11.4.2.2. Aflibercept
    • 11.4.2.3. Ramucirumab
• 11.5. Latin America Market Size (US$ Bn) Forecast, by Type, 2025-2032
  • 11.5.1. VEGF-A Inhibitors
  • 11.5.2. VEGF-B Inhibitors
  • 11.5.3. VEGF-C Inhibitors
  • 11.5.4. Placenta Growth Factor Inhibitors
• 11.6. Latin America Market Size (US$ Bn) Forecast, by Disease Indication, 2025-2032
  • 11.6.1. Oncology
  • 11.6.2. Hematology Disorders
  • 11.6.3. Ophthalmology Disorders
• 11.7. Latin America Market Size (US$ Bn) Forecast, by Distribution Channel, 2025-2032
  • 11.7.1. Hospitals
  • 11.7.2. Specialty Clinics
  • 11.7.3. Mail Order Pharmacies

12. Middle East & Africa Anti-VEGF Market Outlook: Historical (2019-2024) and Forecast (2025-2032)

• 12.1. Key Highlights
• 12.2. Pricing Analysis
• 12.3. Middle East & Africa Market Size (US$ Bn) Forecast, by Country, 2025-2032
  • 12.3.1. GCC Countries
  • 12.3.2. South Africa
  • 12.3.3. Northern Africa
  • 12.3.4. Rest of MEA
• 12.4. Middle East & Africa Market Size (US$ Bn) Forecast, by Drug, 2025-2032
  • 12.4.1. Small Molecules
    • 12.4.1.1. Pazopanib
    • 12.4.1.2. Sunitinib
    • 12.4.1.3. Sorafenib
    • 12.4.1.4. Regorafenib
    • 12.4.1.5. Cabozantinib
    • 12.4.1.6. Lenvatinib
  • 12.4.2. Biologics
    • 12.4.2.1. Bevacizumab
    • 12.4.2.2. Aflibercept
    • 12.4.2.3. Ramucirumab
• 12.5. Middle East & Africa Market Size (US$ Bn) Forecast, by Type, 2025-2032
  • 12.5.1. VEGF-A Inhibitors
  • 12.5.2. VEGF-B Inhibitors
  • 12.5.3. VEGF-C Inhibitors
  • 12.5.4. Placenta Growth Factor Inhibitors
• 12.6. Middle East & Africa Market Size (US$ Bn) Forecast, by Disease Indication, 2025-2032
  • 12.6.1. Oncology
  • 12.6.2. Hematology Disorders
  • 12.6.3. Ophthalmology Disorders
• 12.7. Middle East & Africa Market Size (US$ Bn) Forecast, by Distribution Channel, 2025-2032
  • 12.7.1. Hospitals
  • 12.7.2. Specialty Clinics
  • 12.7.3. Mail Order Pharmacies

13. Competition Landscape

• 13.1. Market Share Analysis, 2024
• 13.2. Market Structure
  • 13.2.1. Competition Intensity Mapping
  • 13.2.2. Competition Dashboard
• 13.3. Company Profiles
  • 13.3.1. Pfizer Inc.
    • 13.3.1.1. Company Overview
    • 13.3.1.2. Product Portfolio/Offerings
    • 13.3.1.3. Key Financials
    • 13.3.1.4. SWOT Analysis
    • 13.3.1.5. Company Strategy and Key Developments
  • 13.3.2. Bayer AG
  • 13.3.3. Novartis AG
  • 13.3.4. Sanofi SA
  • 13.3.5. Exelixis Inc.
  • 13.3.6. Eisai Co. Ltd.
  • 13.3.7. Amgen Inc.
  • 13.3.8. F. Hoffmann-La Roche Ltd.
  • 13.3.9. Eli Lilly and Company
  • 13.3.10. Amneal Pharmaceuticals Inc.
  • 13.3.11. Jiangsu Hengrui Pharmaceuticals Co. Ltd.
  • 13.3.12. Takeda Pharmaceutical Co. Ltd.
  • 13.3.13. Sino Biopharma
  • 13.3.14. HUTCHMED

14. Appendix

• 14.1. Research Methodology
• 14.2. Research Assumptions
• 14.3. Acronyms and Abbreviations